Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Cognitive Function
Interventions: Placebo Control Form 1, Clarity Active Study Product 1.1 Usage, Placebo Control Form 2, Clarity Active Study Product 2.1 Usage, Placebo Control Form 3, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 3.2 Usage, Placebo Control Form 4, Clarity Active Study Product 4.1 Usage, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage, Placebo Control Form 6, Clarity Active Study Product 6.1 Usage, Placebo Control 6.1.0, Clarity Active Study Product 6.1.1 Usage, Clarity Active Study Product 6.1.2 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 4,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Alzheimer Disease
Interventions: Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 37
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Drug Interactions
Interventions: Rosuvastatin, Rosuvastatin + BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: Obesity
Interventions: AMRA(r) Researcher Image reconstruction software, MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.), MRI: Research pulse sequences (Device Manufacturer: NIH), MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH), Bluetooth-enabled glucometer, Remote tailored-to-place coaching (TPC), Standard remote coaching (SRC), Run-in physical-activity monitoring, Ambulatory blood-pressure monitor, Polysomnography equipment; Device · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Toms River, New Jersey • Asheville, North Carolina • Kingsport, Tennessee + 1 more

Conditions: Obesity
Interventions: Tapered Low Calorie Diet, Traditional Low-Calorie Diet; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Smoking
Interventions: guanfacine, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions: High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate
Interventions: Cannabis Actions and Practices Resource for Parents; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 13 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post-Traumatic Headache
Interventions: sumatriptan/naproxen sodium, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Springfield, Missouri • Nashville, Tennessee • Temple, Texas

Conditions: Pharmacokinetics
Interventions: DS-8500a, Itraconazole; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions: Dimethyl fumarate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Huntington's Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more

Conditions: Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Lenalidomide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Liver Disease
Interventions: isoflurane, propofol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: ALXN2050, Fluconazole, Rifampin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions: Volanesorsen; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more

Search by objective public record fields.

Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

Efficacy and Safety Study in Subjects With Asthma

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Trial Comparing PLA to HIGRT (PROVE-HCC)

Clinical Evaluation of BD NEXT Pen Needle

The TREND Study: Tapered Reduction in Energy Intake as a Novel Approach to Dieting

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

Modeling Stress-precipitated Smoking Behavior for Medication Development

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

Dimethyl Fumarate for Obstructive Sleep Apnea

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Omalizumab Before Onset of Exacerbations

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Isoflurane Preconditioning for Liver Resections

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome